Supplementary Table 7. Changes from baseline in lipid profile

Variable	Enavogliflozin 0.3 mg ($n=93$)	Dapagliflozin 10 mg ($n=87$)
Total cholesterol, mg/dL		
Baseline	151.43 (32.91)	137.87 (26.64)
Week 24	159.42 (32.17)	147.02 (27.55)
Change from baseline at week 24		
LS mean (SE)	9.13 (2.22)	6.74 (2.30)
LS mean difference (95% CI), *P* value	2.40 (−3.74 to 8.53), *P*=0.4422	
LDL-C, mg/dL		
Baseline	86.52 (30.53)	76.16 (26.27)
Week 24	87.40 (29.52)	78.84 (25.81)
Change from baseline at week 24		
LS mean (SE)	1.64 (1.92)	0.93 (1.98)
LS mean difference (95% CI), *P* value	0.71 (−4.56 to 5.99), *P*=0.7898	
HDL-C, mg/dL		
Baseline	50.94 (10.85)	46.90 (9.17)
Week 24	53.69 (10.72)	50.45 (9.72)
Change from baseline at week 24		
LS mean (SE)	3.06 (0.64)	3.19 (0.66)
LS mean difference (95% CI), *P* value	−0.14 (−1.90 to 1.63), *P*=0.8788	
Triglyceride, mg/dL		
Baseline	122.10 (85.91)	132.92 (75.63)
Week 24	119.62 (58.93)	122.28 (58.14)
Change from baseline at week 24		
LS mean (SE)	−5.07 (5.14)	−6.70 (5.28)
LS mean difference (95% CI), *P* value	1.63 (−12.36 to 15.63), *P*=0.8181	

Data were analyzed using the modified per-protocol set 1.
SE, standard error; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.